Endoscope firm Mauna Kea Technologies grew its revenues by 10 percent in 2014 despite a sales slowdown in the U.S. Sales were €11.0 million, compared to €10.0 million in 2013, with hospitals representing 78 percent of the company’s business. Mauna Kea sold 88 systems and 896 probes, compared with 73 and 688 in 2013, demonstrating sales growth by volume of 21 percent for equipment and 30 percent for consumables. Mauna Kea develops medical devices for endomicroscopy and optical biopsy. Its flagship product is the confocal laser endomicroscopy platform Cellvizio. The company recently formed a clinical partnership with Siemens to evaluate Cellvizio for use in interventional radiology procedures. For more information, visit www.maunakeatech.com.